Key Dates:
30 June 2011 - Abstract submission
15 July 2011 - Notification of final acceptance of
papers
15 July 2011 - Deadline for early bid registration
Registration
Meeting registration is only available via e-mail to
[email protected]
Abstracts must be submitted via e-mail as attachments to:
[email protected]. The attachment should be a Microsoft Word
document. Faxed abstracts will not be considered. Please read
the rules of submission before submitting your abstract.
At least one of the author must be registered at the meeting.
Rules for submission to the 2011 AISAL Congress:
AISAL
Associazione Italiana per le Scienze degli Animali da Laboratorio
FELASA Constituent Association
Abstract Title:
Abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the research.
Author Name(s):
The name of presenting author should be underlined.
Any abstract changes will not be permitted after July 15, 2011.
Abstracts should be in English.
Biomaterials in medicine
and animal models
Abstract Text:
ICSU satellite meeting supported by:
In the abstract text the research objectives, methods, results and
conclusion should be briefly summarized. References and grant
support shouldn’t be included.
Registration fees:
Before After 15
15 July
July
2011
2011
Standard registration
AISAL
member
Student
*
€ 150
€ 200
€ 100
€ 150
€ 20
€ 50
* Evidence of student status, such as copy of official
Abstracts are limited to 2,500 characters, excluding the abstract
title, and author names. Punctuation marks and spaces count as
characters. Tables/graphics and figures shouldn’t be included.
Accepted abstracts will be published online in Comparative Medicine (I.F.1.094;http://www.aalas.org/publications/
index.aspx#cm), as well as on the AISAL website.
Scientific awards
Università di Napoli Federico II
AISAL awards two prizes for Young Scientists, one for the best
oral presentation and one for the best poster. These prizes are
reserved to AISAL members aged 35 years or younger. For both
prizes the first author will be awarded. Both awards will be presented at the Closing Ceremony of the Congress.
The papers will be judged and ranked by the Scientific Committee. The winner will be awarded with an individual certificate and:
enrollment letter, has to accompany registration.
Registration fees cover:
- All sessions of the scientific program.
- Scientific proceedings.
- Meeting bag and contents.
- Coffee breaks and lunches.
500€
for
the
best
poster
1000 € for the best oral presentation
contribution
September 22-23, 2011
Congress Center
University of Naples Federico II
Via Partenope, 36
NAPLES
Biomaterials in medicine and animal models
A biomaterial is any kind of material that interacts with biological
systems, and can be used to treat, enhance or replace any tissue,
organ or function in an organism. Biomaterials also refers to
biologically-derived materials used for their structural rather than
biological properties, e.g. collagen (a protein found in the skin,
connective tissues and bone) as a cosmetic ingredient. Also,
carbohydrates (biotechnologically modified) are being used as
lubricants for biomedical applications and as bulking agents in
the food industry. Biomaterials are required to act harmoniously
Invited Speakers:
Polymer based biomaterials for tissue regeneration.
Luigi Ambrosio
Institute for Composite and Biomedical Materials,
National Research Council, Napoli
DegraPol®: Life-sustaining Polymeric Material
Eliana Bonavoglia
Ab Medica, Milano
when exposed to the body or bodily fluids. Investigating cellular or
in vivo phenotypic responses helps to determine the associated
biocompatibility. Biocompatibility is the use or design of a material harmless to the host tissue, achieved either with chemical and
biological inertness or successful integration with the surrounding
proteins and cells. A material that is considered biocompatible
will have extensive applications in human health care, which
could improve a patient’s quality of life and elongate life expectancy. The goal of the in vivo assessment of biocompatibility is to
predict whether a medical device presents potential harm to the
patient or user by evaluation under conditions simulating clinical
use. For the in vivo assessment of biomaterials, medical devices
in their final form and condition are commonly implanted in
carefully selected animal models to determine function as well as
biocompatibility. The main in vivo tests for biocompatibility are:
sensitization, irritation, intracutaneous reactivity, systemic toxicity
(acute toxicity), subchronic toxicity (subacute toxicity), genotoxicity, implantation, hemocompatibility, chronic toxicity, carcinogenicity, reproductive and developmental toxicity, biodegradation,
immune responses. It is clear that the animal models are key to
in vivo testing, and furthermore , experimental design of the
animal tests must enable reproducible and accurate outcome
data that can be quantified. The aim of this meeting is to update
and share the latest developments regarding the contribution of
animal models in the development of biomaterials with attention
to new frontiers on biomaterials, animal models (criteria of selection and description of newly models), how the actual researches
can push the clinical innovations, and the ethical and legislative
aspects.
Regenerative therapy in veterinary medicine: from
bench to patient. An overview.
Maurizio Del Bue
University of Parma
Biotechnology and animal ethics: between
anthropocentrism and pathocentrism.
Kris Dierickx
Centre for Biomedical Ethics and Law,
Katholieke Universiteit Leuven
Preclinical models to evaluate biomaterials for
orthopaedic applications.
Roberto Giardino
Laboratory of Preclinical and Surgical
Studies, Rizzoli Orthopaedic Institute,
Bologna
From mice to men - the relevance of animal models
for bone research.
Anita Ignatius
Institute of Orthopaedic Research and
Biomechanics, University of Ulm
Animal welfare requirements for biomaterial research.
Lucia Martini
Rizzoli Orthopaedic Institute, Bologna
Cardiovascular regenerative medicine in a smallanimal model of acute myocardial infarction.
Carlo Ventura
Alma Mater Studiorum, University of Bologna
Scientific Committee:
Luigi Ambrosio, National Research Council
Gianni Dal Negro, GlaxoSmithKline
Paolo de Girolamo, University of Naples Federico II
Roberto Di Lauro, Zoological Station A. Dohrn, University of
Naples Federico II
Barbara Dozza, Rizzoli Orthopaedic Institute, Bologna
Alessandro Fioretti, University of Naples Federico II
Enrico Lucarelli, Rizzoli Orthopaedic Institute, Bologna
Paolo Netti, University of Naples Federico II
Organizing Committee:
Andrea Affuso, Biogem, Ariano Irpino
Marcello Raspa, CNR-IBC-EMMA, Monterotondo
Andrea Tamellini, Aptuit, Verona
Valentina Vasina, University of Bologna "Alma Mater Studiorum"
Scientific and organizing secretary:
Laura De Francesco, Guido Bernardini Foundation, Milano
Valentina Vasina, University of Bologna "Alma Mater Studiorum"